Company Information

Location

Cambridge, UK

CEO

Niall Martin

Website

www.artiospharma.com

Social

LinkedIn

Many cancers change their DDR pathways in order to evolve and adapt, and which can also cause them to overcome many current therapies through resistance. Targeting the remaining DDR pathways has been proven to selectively kill cancer cells through synthetic lethality. DDR targeted products have the potential to be used in combination with other cancer agents to help prevent cancers from reoccurring.

Established in July 2016, Artios is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. The Company is building a pipeline of next-generation DDR programmes, including partnerships with Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide.